Ask AI
ProCE Banner Activity

How I Manage Key Toxicities With Adjuvant CDK4/6 Inhibitors for Early Breast Cancer

Clinical Thought

Patients benefit the most from adjuvant CDK4/6 inhibitor therapy for HR-positive, HER2-negative early breast cancer when healthcare professionals quickly identify and manage toxicities. In this commentary, I share guidance on managing the most common and challenging toxicities: diarrhea with abemaciclib and neutropenia with ribociclib.

Released: December 22, 2023

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Breastcancer.org and Smart Patients Inc.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Smart Patients

ProCE Banner

Disclosure

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor: AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Duality, Eisai, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead, Guardant Health, Hibercell, Jazz, Johnson & Johnson, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Sanofi, Seagen, Stemline, Summit, Tempus, TerSera.

Sara M. Tolaney, MD, MPH

Chief, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo Therapeutics, Bayer, BeOne Therapeutics, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Gilead, GNE/Roche, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer/SeaGen, Reveal Genomics, Sumitovant Biopharma, Summit Therapeutics, Tango Therapeutics, Zuellig Pharma; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.

Primary Author

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, AOCNP, has no relevant financial relationships to disclose.